The insider selling is routine in both dollar amount and proportion to market cap. No single insider sold a material stake. The cluster does not signal distress or a negative catalyst, it is consistent with normal portfolio diversification after a strong stock run. Monitor for any unexpected insider buying or a sudden increase in selling volume, but no immediate action is warranted.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $69.42entry
- T+1 · 7mo ago −0.42%α −0.08% · $69.13
- T+5 · 6mo ago +8.10%α +5.76% · $75.05
- T+20 · 6mo ago +1.61%α −3.67% · $70.54
- T+60 · 4mo ago +43.99%α +40.92% · $99.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four insiders at Spyre Therapeutics, including the CEO, CFO, and CMO, sold a total of $2.92M in open-market sales over a 7-day window ending May 8, 2026. The sales follow a Q1 earnings report showing a wider net loss of $69.0M, though the company highlighted positive Phase 2 data and a strong cash runway. The cluster value represents ~0.05% of the $6.3B market cap, which is trivial and routine for a biotech of this size.
Key Financial Metrics
Key Facts
- Four insiders sold shares totaling $2.92M in open-market transactions from May 1-8, 2026.
- CEO Turtle Cameron sold $369K, CFO Scott Burrows sold $892K, CMO Sheldon Sloan sold $1.48M, and Director Michael Henderson sold $174K.
- Total cluster value is ~0.05% of SYRE's $6.3B market cap, well below the 0.1% materiality threshold.
- Sales occurred 4 days after Q1 2026 earnings reported a net loss of $69.0M, wider than the $44.8M loss in Q1 2025.
- The company has a pro forma cash position of $1.18B following a $463M public offering, with runway into H2 2029.
- Prior 30-day insider activity included $2.9M in sells, consistent with routine insider selling patterns.
Financial Impact
Insider sales of $2.92M represent 0.05% of market cap, immaterial from a capital markets perspective.
Risk Factors
- Insider selling could accelerate if the stock continues to rally or if pipeline data disappoints.
- Wider net losses and pre-revenue status mean the stock is highly sensitive to clinical trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SYRE-1778290336581 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers